| タイトル |
Renal protective effects of empagliflozin via inhibition of EMT and aberrant glycolysis in proximal tubules
|
| 著者 |
Li Jinpeng
Liu Haijie
Takagi Susumu
Nitta Kyoko
Kitada Munehiro
Srivastava Swayam Prakash
Takagaki Yuta
Koya Daisuke
|
| 収録物名 |
JCI INSIGHT
|
| 巻 | 5 |
| 号 | 6 |
| 収録物識別子 |
EISSN 2379-3708
|
| 言語 |
英語
|
| 資源タイプ | 学術雑誌論文 |
| 出版者 |
AMER SOC CLINICAL INVESTIGATION INC
|
| 発行日 | 2020-03-26 |
| アクセス権 | メタデータのみ |
| 関連情報 |
[DOI] 10.1172/jci.insight.129034
[PMID] 32134397
|
| 備考 | Empagliflozin was provided by Boehringer Ingelheim through a material transfer agreement. This study was essentially supported by a 2016 grant from the Japan Diabetes Foundation. This work was partially supported by the Japan Society for the Promotion of Science to KK (grants 23790381 and 23790381) and DK (grants 25282028 and 25670414). This work was partially supported by Grants for Collaborative Research awarded to DK (C2011-4 and C2012-1) and Grants for Promoted Research awarded to KK (S2015-3, S2016-3, and S20171) from Kanazawa Medical University. Boehringer Ingelheim, Mitsubishi-Tanabe Pharma, and Ono Pharmaceutical contributed to establishing the Division of Anticipatory Molecular Food Science and Technology. |
